Ovarian Cancer, Chemotherapy Resistance, and the Body's Internal Clock: What Patients Should Know

Table of Contents

• Key Points
• Background: Why Ovarian Cancer Research Matters
• The Main Types of Ovarian Cancer
• Inherited Risk and Genetic Testing
• Standard Treatment and the Problem of Resistance
• How Chemoresistance Develops: The Six Core Mechanisms
• Drug Efflux Pumps: Pumping Chemotherapy Out of Cells
• Multidrug Resistance and Its Genetic Markers
• The Tumor Microenvironment and Immune Cells
• Epigenetic Factors: Switching Genes On and Off
• MicroRNAs: Tiny Regulators With Big Effects
• Apoptosis: When Cancer Cells Refuse to Die
• Autophagy: Cancer Cells Recycling to Survive
• The Circadian Rhythm: Your Body's 24-Hour Clock
• How Circadian Rhythm Affects Ovarian Cancer Risk
• Clinical Implications: What This Means for Patients
• Limitations: What This Research Could Not Prove
• Practical Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Ovarian cancer is the seventh most common cancer in women worldwide and the eighth leading cause of cancer death; most cases are diagnosed at advanced stages.
• About 1 in 10 epithelial ovarian tumors is genetically based, mostly from BRCA1 or BRCA2 mutations; BRCA1 carries a 40% to 50% lifetime risk, BRCA2 20% to 30%.
• Standard treatment is platinum-based chemotherapy plus surgery, but resistance can develop through drug efflux pumps, epigenetic changes, microRNAs, apoptosis blockade, and autophagy.
• Some resistance machinery, such as higher MDR1, LRP, and GSTP1, was found in patients who had never received chemotherapy or radiation, suggesting tumors can be pre-wired for resistance.
• Night shift work is associated with higher rates of ovarian tumors in women aged 50 and above, but this is an association, not proof of cause.

Background: Why Ovarian Cancer Research Matters

Ovarian cancer (cancer that begins in the ovaries) is the seventh most common cancer type in women globally. It ranks as the eighth leading cause of cancer-related deaths in women. These two facts together tell an important story: ovarian cancer is not the most common cancer, but it is one of the deadliest.

Where a woman lives appears to affect her risk. Incidence rates are higher in developed regions and lower in less developed countries. However, these patterns are shifting. In high-income countries, new cases have been declining in recent years. In low-income countries, new cases have been rising.

Perhaps the most important statistic for patients is this: most ovarian cancer cases worldwide are diagnosed at advanced stages. Late diagnosis complicates treatment and lowers the chances of survival. As the authors note in the context of Turkey, early diagnosis, raising public awareness, obesity management, and healthy practices such as smoking cessation are all crucial for fighting this disease.

The Main Types of Ovarian Cancer

Ovarian cancer is not a single disease. It comes in several forms, and each one behaves differently and responds differently to treatment.

A small proportion of ovarian malignancies — usually in women under 40 years old — begin in the germ cells (the egg-producing cells) and stromal cells (the hormone-producing structural cells) inside the ovary. The vast majority, however, are epithelial malignancies, meaning they start in the epithelial cells that line the ovary's surface.

Epithelial ovarian cancers are genetically and biologically diverse. Doctors classify them into five main histotypes (tumor types based on how the cells look under a microscope):

• High-grade serous — the most common type
• Low-grade serous
• Endometrioid
• Clear cell
• Mucinous

Each of these five types responds differently to chemotherapy. There are also borderline serous and mucinous neoplasms (abnormal growths). These show high proliferation (rapid cell division) and atypia (abnormal cell appearance) compared with benign (non-cancerous) tumors, but they are less distinct than low-grade carcinomas.

Where do these tumors actually start? Research points to a surprising answer. The predominant histotype, high-grade serous cancer, appears to originate from serous tubal intraepithelial carcinoma (STIC) lesions — early abnormal cell patches found at the fimbriae, the finger-like ends of the fallopian tubes. Endometrioid and clear cell malignancies, by contrast, likely develop in areas of endometriosis (tissue similar to the uterine lining growing outside the uterus).

Inherited Risk and Genetic Testing

Family history is the single most important risk factor for ovarian cancer. Hereditary ovarian cancer appears in three clinical patterns:

1. Regional (site-specific) ovarian cancer
2. Breast-ovarian cancer syndrome
3. Hereditary nonpolyposis colorectal cancer (HNPCC), also called Lynch II syndrome

The first two patterns are linked to germline mutations (inherited gene changes present from birth) in the tumor suppressor genes BRCA1 and BRCA2 (Breast Cancer Gene 1 and 2). HNPCC is connected to germline mutations in DNA mismatch repair (MMR) genes — specifically hMLH1 (mutL homolog 1) and hMSH2 (MutS homolog 2). These MMR genes normally fix errors made when DNA is copied; when they fail, errors accumulate.

How common is inherited ovarian cancer? At least 10% of all epithelial ovarian tumors — about 1 in 10 — are genetically based. BRCA gene mutations account for more than 90% of these inherited cases, while most of the remaining 10% are associated with HNPCC.

The lifetime risk numbers are striking and worth stating clearly:

• Women with a BRCA1 mutation face a cumulative lifetime ovarian cancer risk of 40% to 50% — roughly 4 to 5 in 10.
• Women with a BRCA2 mutation face a lifetime risk of 20% to 30% — roughly 2 to 3 in 10.

Ovarian tumors linked to germline BRCA mutations are typically detected at younger ages and are characterized as high-grade advanced serous carcinomas.

Modern next-generation sequencing (a technology that reads many genes at once) now allows simultaneous analysis of numerous cancer susceptibility genes. This reduces delays and costs while improving molecular diagnosis of hereditary tumors. Identifying mutations in ovarian cancer susceptibility genes in healthy women may enable more personalized cancer risk management through individualized clinical and radiological monitoring, chemopreventive strategies (medications to lower risk), and/or prophylactic surgery (preventive removal of at-risk tissue). Conversely, finding mutations in women who already have ovarian cancer may reveal targets for biological therapies and inform treatment decisions.

Standard Treatment and the Problem of Resistance

The preferred treatment for ovarian cancer is platinum-based chemotherapy combined with surgical intervention. Platinum resistance, however, remains a significant medical problem. To optimize medical benefits and improve patient outcomes, researchers emphasize the need to identify robust biomarkers (measurable biological signals) and therapeutic targets alongside personalized treatment.

Cisplatin (cis-[PtCl₂(NH₃)₂], abbreviated DDP) was the first platinum-based complex approved by the FDA (U.S. Food and Drug Administration) for treating several cancers, including cervical, colorectal, lung, recurrent lymphoma, and ovarian cancer. Cisplatin works primarily by triggering a DNA damage response that causes cancer cells to die.

Unfortunately, the effectiveness of cisplatin in ovarian cancer cells diminishes over time as drug resistance develops.

How Chemoresistance Develops: The Six Core Mechanisms

Chemoresistance in ovarian cancer is a complex problem that significantly impedes treatment efficacy. Many pathways contribute, including genetic factors, interactions within the tumor microenvironment (the surrounding tissue, blood vessels, and immune cells), and lifestyle variables such as obesity. Understanding these mechanisms is crucial for developing effective treatment solutions.

The mechanisms of drug resistance in ovarian cancer cells include six major categories:

• Reduced intracellular drug concentration (less drug gets inside the cell)
• Enhanced detoxification (the cell neutralizes the drug)
• Augmented DNA repair and damage response (the cell fixes the damage cisplatin causes)
• Deregulation of apoptosis (failure of programmed cell death)
• Alterations in the tumor microenvironment
• Evasion of the host immune response

Cisplatin resistance depends on the variability of DNA damage and apoptotic mechanisms, which results from the non-specificity of how cisplatin binds DNA. Researchers categorize resistance by when it occurs:

• Pre-target resistance — alterations that happen before cisplatin binds to its cellular targets
• On-target resistance — modifications in the DNA-cisplatin adducts (drug-DNA complexes) themselves
• Post-target resistance — mutations and changes in downstream signaling pathways that normally trigger apoptosis
• Off-target resistance — modifications in cellular pathways not directly associated with cisplatin-induced signaling

Drug Efflux Pumps: Pumping Chemotherapy Out of Cells

Drug efflux proteins play a crucial role in treatment resistance. To work, chemotherapy drugs must reach the cell cytoplasm (the fluid inside the cell). Efflux proteins prevent this by actively expelling drugs from the cell before they can do harm.

The main drug efflux and membrane transporter proteins associated with resistance belong to the adenosine triphosphate-binding cassette (ABC) superfamily. ABC transporters use adenosine triphosphate (ATP, the cell's energy currency) to move substances across the cell membrane.

Structurally, these transporters consist of two cytoplasmic nucleotide-binding domains that recognize the molecules to be transported, and two transmembrane domains that handle ATP binding and hydrolysis (breaking down ATP for energy). This large protein family divides into seven subfamilies, labeled A through G, based on sequence homology (how similar their genetic sequences are).

Three specific proteins are tied to chemotherapy resistance in ovarian cancer:

• ABCB1 (P-glycoprotein, or PgP; also called multidrug resistance protein 1, or MDR1)
• ABCC1 (multidrug resistance-associated protein 1, or MRP1)
• ABCG2 (breast cancer resistance protein, or BCRP)

Multidrug Resistance and Its Genetic Markers

In many cancer types, resistance to chemotherapy is mostly attributed to multidrug resistance in cancer cells. The MDR1 gene encodes the P-glycoprotein drug transporter. High MDR1 gene expression — or high P-glycoprotein levels — is considered a marker of drug resistance.

Notably, researchers have found that the resistance genes MDR1, LRP (Lung Resistance Protein), and GSTP1 (Glutathione S-transferase P1) are significantly higher in epithelial ovarian cancer patients who have never received chemotherapy or radiation therapy, compared with patients who have borderline adenoma or benign adenoma. In other words, resistance machinery can be present before treatment even begins.

Multidrug resistance-associated proteins (MRPs) matter greatly in ovarian cancer. Studies show that microRNAs (small RNA molecules that regulate gene activity) modulate the expression of MDR efflux transporters in the ABC superfamily across various tumors — by upregulating MRP3, MRP4, and MRP5, and by expressing MRP7.

Looking at the transporters individually:

• ABCB1 (P-glycoprotein/MDR1) is the most extensively studied member. It is frequently overexpressed in cisplatin- and paclitaxel-resistant ovarian cancer models and works as an ATP-dependent efflux pump that reduces drug accumulation and drug-induced cell killing.
• ABCC1 (MRP1) and related transporters (ABCC3, ABCC4, ABCC5, ABCC10/MRP7) transport platinum derivatives out of the cell along with glutathione and glucuronide conjugate metabolites. They also support redox homeostasis (the cell's chemical balance) and survival under chemotherapy-induced stress.
• ABCG2 (BCRP) is highly expressed in ovarian cancer stem-like cells. There it facilitates efflux of agents such as cisplatin and topotecan and is strongly associated with the maintenance of stem cell properties and tumor recurrence.

The expression of these transporters is regulated on multiple levels. For example, miR-130a is upregulated in cisplatin-resistant SKOV3/CIS cells; blocking it reduces MDR1 expression and restores cisplatin sensitivity. A more comprehensive study confirmed that miR-27a and miR-130a increase P-gp expression and contribute to drug resistance in ovarian cancer.

Additionally, alternative polyadenylation (APA) of ABCC1 transcripts has been reported in high-grade serous ovarian cancer. This process produces truncated 3′UTR variants that escape microRNA-mediated suppression, thereby maintaining high transporter levels — which confers resistance and poor survival.

Together, these findings show that ABCB1, ABCC1, and ABCG2 do more than pump drugs out. They also support apoptosis escape, redox stability, and stem cell properties. Their regulation by microRNAs and APA provides further insight into the post-transcriptional mechanisms (controls that act after a gene is read) of chemotherapy resistance.

The Tumor Microenvironment and Immune Cells

The tumor microenvironment may contribute to both recurrence and resistance to chemotherapy. Tumor-associated macrophages (TAMs) are the predominant immune cell type within the ovarian tumor microenvironment. These cells play a significant role in the progression of ovarian cancer and in resistance to chemotherapy.

The primary tumor-supporting role of M2-like TAMs is to activate survival signaling pathways. They do this by releasing various cytokines, chemokines, enzymes, and exosomes (tiny packets that carry molecular cargo). These signals help microRNAs gain access to cancer cells and directly increase the invasion potential and chemotherapy resistance of ovarian cancer cells.

Researchers suggest that this complex interaction between ovarian cancer cells and tumor-associated macrophages contributes to treatment failure. While the role of TAMs in chemotherapy resistance is widely accepted in breast cancer, it has also been shown to be significant in ovarian cancer. The main mechanisms of TAM-associated chemotherapy resistance in ovarian cancer include:

1. Tumor-supporting polarization of macrophages (shifting them into a cancer-friendly state)
2. Their effects on survival signaling pathways
3. Activation of multidrug resistance genes in cancer cells, mediated by macrophages

Epigenetic Factors: Switching Genes On and Off

Epigenetic changes are modifications that affect gene activity without changing the DNA sequence itself. These include DNA methylation (chemical tags added to DNA), histone modifications (changes to the proteins DNA wraps around), and non-coding RNA regulation. All three play significant roles in ovarian cancer treatment resistance.

Epigenetic changes drive resistance through multiple pathways, including modulation of multidrug resistance-associated protein expression, alteration of the tumor microenvironment, and dysregulation of the immune response.

Specific laboratory findings illustrate how this works:

• Sun and colleagues showed that paclitaxel treatment enhanced histone H3 acetylation and specifically targeted the androgen receptor (AR) and ABCB1 promoter. This resulted in ABCB1 gene expression and the development of a paclitaxel resistance phenotype.
• Wang and colleagues showed that hnRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1) binds to the 5'UTR of ABCC2 mRNA, increasing its translation and leading to cisplatin resistance in ovarian cancer.
• Calcagno and colleagues found that increased acetylation of histone H3 in the ABCG2 promoter underlies doxorubicin resistance.

These findings demonstrate that epigenetic control significantly affects resistance to ovarian cancer treatment by modifying the ABC transporter family.

DNA methylation changes are especially important. DNA hypermethylation (excess methylation) of tumor suppressors such as BRCA1/2, MLH1, and RASSF1A leads to impaired DNA repair, inadequate mismatch repair, or loss of apoptotic signaling — thereby promoting platinum resistance and poor prognosis. Conversely, hypomethylation (too little methylation) of oncogenes — including HOXA9, CBX8, AGR2, and GABRP — has been associated with tumor progression and metastasis.

Methylation-induced silencing of regulators in the Wnt/β-catenin pathway (SFRP5, IQGAP2, TMEM88) and the TGF-β pathway (FBXO32, ABCA1, SOX2, TGFBI) further facilitates epithelial-mesenchymal transition (EMT, a process where cancer cells gain the ability to spread), increased proliferation, and resistance to platinum therapy. Methylation changes in genes associated with EMT, such as MSX1 and LAMA3, also contribute to the emergence of cancer stem cells (CSCs), which are closely linked to drug resistance.

Encouragingly, clinical studies with DNMT inhibitors (drugs that block DNA methylation) — including azacitidine, decitabine, and guadecitabine — have shown that targeting methylation can overcome platinum resistance and enhance immune responses.

Histone modifications similarly affect chemotherapy sensitivity. Overexpression of histone deacetylases (HDACs), particularly HDAC1 and HDAC6, has been associated with tumor progression and poor clinical outcomes. HDAC-mediated hypoacetylation silences proapoptotic genes such as BAX and p21. Pharmacologic inhibition of HDACs has been shown to restore apoptosis and re-sensitize resistant ovarian cancer cells to cisplatin and paclitaxel.

MicroRNAs: Tiny Regulators With Big Effects

MicroRNAs form bidirectional regulatory loops with the circadian clock. They also intersect with the pathways that govern drug efflux and apoptosis in ovarian cancer. For example, miR-142-3p is transcriptionally regulated by CLOCK:BMAL1 (two core clock proteins), directly targets the 3′UTR of BMAL1, and forms a negative feedback module within the nuclear oscillator (the cell's internal timekeeping machinery).

In ovarian cancer models, several microRNAs modulate chemoresistance by controlling ABC transporters and survival signaling:

• miR-130a is upregulated in cisplatin-resistant cells. Blocking it reduces MDR1/P-glycoprotein (ABCB1) and restores cisplatin sensitivity.
• miR-27a promotes paclitaxel resistance by increasing MDR1/P-gp, at least partly through HIPK2.
• miR-186 enhances sensitivity to both paclitaxel and cisplatin by directly targeting ABCB1.
• miR-34a, a tumor-suppressive microRNA, reduces proliferation and rescues platinum sensitivity by repressing HDAC1 and BCL-2-linked anti-apoptotic pathways.
• miR-9 downregulates BRCA1 and enhances sensitivity to cisplatin and PARP (Poly (ADP-ribose) Polymerase) inhibitors by inhibiting DNA damage repair.
• miR-490-3p reduces ABCC2/MRP2 levels and improves responsiveness to cisplatin.
• miR-214 targets PTEN to activate PI3K/AKT signaling and inhibit apoptosis.
• The miR-200 family controls EMT and thereby modulates platinum sensitivity.

Additional microRNAs — including miR-9, miR-520d-3p, miR-206, and miR-93 — have been linked to chemosensitivity and prognosis.

Kumar and colleagues showed that microRNAs play a role in cisplatin-resistant cells, potentially targeting numerous critical pathways. These include MAPK (Mitogen-Activated Protein Kinase), TGF-β (Transforming Growth Factor Beta) signaling, the actin cytoskeleton, the ubiquitin-mediated proteasomal pathway, Wnt signaling, mTOR (Mechanistic Target of Rapamycin) signaling, Notch signaling, and apoptosis. Modulating one or more of these microRNAs may represent significant treatment targets for ovarian cancer.

Han and colleagues found that hepatic leukaemia factor (HLF) is elevated in ovarian cancer tissues and ovarian cancer stem cells. HLF governs ovarian cancer cell stemness, proliferation, and metastasis. The study showed that HLF transcriptionally activates Yes-associated protein 1 (YAP1) expression, thereby modulating the Hippo signaling system. Moreover, miR-520e was shown to directly target the HLF 3′-UTR in ovarian cancer cells. The HLF/YAP1 axis was shown to influence the response to carboplatin (another platinum drug).

A longitudinal study of microRNA expression patterns in high-grade serous ovarian cancer (HGSOC) patients undergoing neoadjuvant chemotherapy (NACT, chemotherapy given before surgery) produced important clinical findings. The expression levels of miR let-7G-5p, miR-199a-3p, miR-199a-5p, and miR-181a-5p were independently correlated with overall survival. These four microRNAs are also related to platinum-based resistance and prognosis. Finally, the co-expression of P-Smad2 and miR-181a-5p in surgical tissues indicates a poor prognosis and a diminished likelihood of responding to platinum-based neoadjuvant chemotherapy.

Apoptosis: When Cancer Cells Refuse to Die

Most anticancer drugs aim to trigger cell death through various mechanisms, including apoptosis (programmed cell death, the body's natural way of eliminating damaged cells). If apoptosis is delayed or inhibited, resistance may develop and reduce the drug's effectiveness.

Because chemotherapy is known to trigger apoptosis in cells, disruptions in the apoptosis pathway can result in resistance. In drug-resistant ovarian cancer, the expression of anti-apoptotic proteins increases after treatment. These proteins inhibit the initiation of apoptosis by directly or indirectly blocking the caspase cascade (a chain of enzymes that carries out cell death).

Two key studies illustrate this. Mano and colleagues discovered that Bcl-2 expression correlated with inadequate response in ovarian cancer tissue samples from patients undergoing cisplatin-based treatment. Yang and colleagues created chemoresistant SKOV3 and OVCAR3 ovarian cancer spheroids (three-dimensional cell clusters) to study platinum resistance. They demonstrated that spheroids exhibited higher Bcl-2 expression compared with ovarian cancer cells grown in monolayers (flat, single-layer cultures). Together, these studies show the significance of Bcl-2 in ovarian cancer and its function as a gene that facilitates drug resistance by inhibiting apoptosis.

Autophagy: Cancer Cells Recycling to Survive

Autophagy is the cell's internal recycling system, breaking down and reusing its own components. In the context of ovarian cancer treatment, it can act as a survival mechanism.

Cisplatin therapy stimulates ERK (Extracellular Signal-Regulated Kinase), thereby facilitating autophagic cell death. Researchers found that inhibiting ERK activation with MEK inhibitors, or reducing ERK expression through siRNA (small interfering RNA, a laboratory tool that silences genes), diminishes cisplatin-induced autophagy. This in turn enhances the sensitivity of ovarian cancer cells to cisplatin-induced death.

Critically, in ovarian cancer cells that gain cisplatin resistance, both ERK activation and autophagy induction are elevated. Suppression of ERK or inhibition of autophagy enhances cisplatin-induced apoptosis in cells that have developed resistance. Consequently, ERK-mediated autophagy may induce resistance to cisplatin. The suppression of autophagy can help overcome cisplatin resistance in ovarian cancer cells.

The Circadian Rhythm: Your Body's 24-Hour Clock

The circadian rhythm, or circadian clock, is an inherent timekeeping mechanism that regulates biological processes in organisms on an approximately 24-hour cycle. This rhythm governs the sleep–wake cycle, body temperature, hormone secretion, metabolism, and many other physiological processes.

At the cellular level, the circadian rhythm governs essential activities including metabolism and DNA repair. It also influences cell cycle genes such as c-Myc, Wee1, cyclin D, and p21 — genes that control how and when cells divide. The circadian rhythm is consequently associated with cancer. The normal operation of these genes is crucial for the organism's health, and their disruption has been linked to numerous disorders.

How Circadian Rhythm Affects Ovarian Cancer Risk

Research indicates that night shift employment correlates with a heightened incidence of both invasive and borderline ovarian tumors, especially the serous and mucinous subtypes, in women aged 50 and above.

Circadian genes are prominently expressed in the ovaries, where they govern ovulation. Circadian disturbance correlates with multiple risk factors for ovarian cancer. This makes the circadian clock a plausible contributor to ovarian cancer development.

Jim and colleagues investigated single nucleotide polymorphisms (SNPs, common single-letter variations in DNA) in the circadian genes BMAL1, CRY2, CSNK1E, NPAS2, PER3, REV1, and TIMELESS, along with the downstream transcription factors KLF10 and SENP3, as predictors of epithelial ovarian cancer (EOC) risk and histological subtypes.

Their investigation revealed that the most notable relationship was rs117104877 in BMAL1. A functional study indicated a notable down-regulation of BMAL1 expression following cMYC overexpression and enhanced transformation in ovarian surface epithelial cells, alongside alternate splicing of BMAL1 exons in ovarian and granulosa cells (the cells surrounding the egg). These findings indicate that variations in circadian genes — particularly BMAL1 — may correlate with ovarian cancer risk, possibly through the disturbance of hormone pathways.

Clinical Implications: What This Means for Patients

This review highlights several findings that could change how ovarian cancer is treated in the future.

First, chemoresistance is not one problem but many. Resistance emerges through drug efflux pumps, epigenetic reprogramming, microRNA signaling, apoptosis blockade, and autophagy. A treatment that targets only one route is unlikely to be enough. This explains why combination strategies are an active area of research.

Second, resistance mechanisms can be present before chemotherapy starts. Higher levels of MDR1, LRP, and GSTP1 were found in epithelial ovarian cancer patients who had never received chemotherapy or radiation. This suggests that some tumors are "pre-wired" for resistance.

Third, several resistance pathways are reversible with drugs that already exist. DNMT inhibitors such as azacitidine, decitabine, and guadecitabine can overcome platinum resistance and enhance immune responses. HDAC inhibitors restore apoptosis and re-sensitize resistant cells to cisplatin and paclitaxel. This is encouraging news for patients whose tumors have stopped responding.

Fourth, the circadian clock may offer a new angle. Night shift work is linked to higher rates of ovarian tumors in women aged 50 and above. Clock gene variations such as BMAL1 rs117104877 may predict ovarian cancer risk. Since the clock influences DNA repair, metabolism, and cell cycle genes, the timing of chemotherapy administration could theoretically matter. However, this remains a research hypothesis rather than an established clinical practice.

Finally, microRNAs such as let-7G-5p, miR-199a-3p, miR-199a-5p, and miR-181a-5p may one day serve as biomarkers. Their expression levels were independently correlated with overall survival and platinum resistance in high-grade serous ovarian cancer patients receiving neoadjuvant chemotherapy.

Limitations: What This Research Could Not Prove

This article is a review, not a new clinical trial. It summarizes laboratory and observational findings rather than reporting the results of a randomized study. As such, it has several important limitations.

• Many findings come from laboratory cell models. SKOV3, OVCAR3, and SKOV3/CIS cells grown in dishes behave differently from tumors in a human body. Spheroid models are more realistic than monolayers but still far from a patient.
• Associations are not causation. The link between night shift work and ovarian tumors is an association. It does not prove that shift work causes ovarian cancer.
• Circadian gene variants need confirmation. The BMAL1 finding (rs117104877) was notable in one study. Independent replication in larger and more diverse populations is needed.
• Reversing resistance in the lab does not guarantee it works in patients. Drugs such as azacitidine, decitabine, guadecitabine, and HDAC inhibitors showed activity in trials and models, but their precise role in ovarian cancer treatment is not yet defined.
• No dosing or timing recommendations are established. This review does not provide guidance on when during the day to give chemotherapy.
• Most patients were diagnosed at advanced stages. This limits what can be learned about early-stage resistance and early detection.

Patients should interpret these findings as promising directions in research, not as currently available treatments.

Practical Recommendations for Patients

Based on this review, here is what patients and their families can reasonably do today:

1. Ask about genetic testing if you have a family history. Family history is the most important risk factor for ovarian cancer. About 1 in 10 epithelial ovarian tumors is genetically based, and BRCA1/BRCA2 mutations carry lifetime risks of roughly 4-5 in 10 and 2-3 in 10 respectively. Knowing your status can guide screening, prevention, and treatment.
2. Discuss your treatment plan with a specialist team. The standard approach combines surgery with platinum-based chemotherapy. Ask whether biomarker testing on your tumor could inform your options.
3. Recognize that resistance can emerge over time. If your cancer stops responding to platinum drugs, this is a known biological phenomenon, not a personal failure. Clinical trials of epigenetic drugs and targeted agents may be worth discussing.
4. Prioritize metabolic and lifestyle health. Obesity is one of the lifestyle variables contributing to resistance pathways. Maintaining a healthy weight, avoiding smoking, and staying physically active support overall health during treatment.
5. Protect your sleep and circadian health. Because circadian disturbance is associated with ovarian cancer risk factors and ovaries express clock genes, maintaining regular sleep–wake patterns is a sensible, low-risk step. If you work night shifts, discuss cancer screening with your doctor.
6. Enroll in clinical trials when eligible. Many of the strategies described here — microRNA targeting, DNMT inhibitors, HDAC inhibitors, and circadian-informed treatment timing — are still under investigation.
7. Seek early evaluation of symptoms. Because most cases are diagnosed at advanced stages, early diagnosis remains one of the most powerful tools available.

Frequently Asked Questions

What is ovarian cancer and how common is it?

Ovarian cancer begins in the ovaries. It is the seventh most common cancer in women worldwide and the eighth leading cause of cancer death. Most cases are diagnosed at an advanced stage, which complicates treatment and lowers survival chances. Incidence is higher in developed regions, though new cases there have been declining while rising in low-income countries.

What are the main types of ovarian cancer?

Most ovarian cancers are epithelial, starting in cells lining the ovary's surface. These are classified into five histotypes: high-grade serous (the most common), low-grade serous, endometrioid, clear cell, and mucinous. Each responds differently to chemotherapy. A small proportion, usually in women under 40, begin in germ cells or stromal cells inside the ovary.

Should I have genetic testing for ovarian cancer risk?

Family history is the most important risk factor. About 1 in 10 epithelial ovarian tumors is genetically based, mostly linked to BRCA1 or BRCA2 mutations. Women with a BRCA1 mutation face a 40% to 50% lifetime risk; BRCA2, 20% to 30%. Testing can guide screening, prevention, and treatment, so discuss it with your doctor if you have a family history.

What is the standard treatment for ovarian cancer?

The preferred treatment is platinum-based chemotherapy combined with surgery. Cisplatin, the first platinum drug approved by the FDA, works by triggering DNA damage that causes cancer cells to die. However, its effectiveness can diminish over time as resistance develops, which remains a significant medical problem and a major focus of research.

What does it mean if my cancer becomes resistant to platinum drugs?

Resistance is a known biological phenomenon, not a personal failure. It can develop through drug efflux pumps, epigenetic changes, microRNAs, blocked apoptosis, autophagy, and tumor microenvironment interactions. Some resistance machinery may be present before treatment starts. If your cancer stops responding, ask your specialist team about clinical trials of epigenetic drugs and targeted agents.

Can lifestyle changes help during ovarian cancer treatment?

Obesity is one lifestyle variable contributing to resistance pathways. Maintaining a healthy weight, avoiding smoking, and staying physically active support overall health during treatment. Because circadian disturbance is associated with ovarian cancer risk factors, keeping regular sleep–wake patterns is a sensible, low-risk step. If you work night shifts, discuss cancer screening with your doctor.

Is there a link between night shift work and ovarian cancer?

Research indicates night shift employment correlates with a heightened incidence of invasive and borderline ovarian tumors, especially serous and mucinous subtypes, in women aged 50 and above. This is an association, not proof that shift work causes cancer. Variations in clock genes such as BMAL1 may also correlate with risk, but findings need confirmation in larger studies.

My ovarian cancer has stopped responding to platinum chemotherapy — when should I seek a second opinion?

Platinum resistance is a known biological phenomenon, not a personal failure, and it emerges through several routes at once — drug efflux pumps, epigenetic changes, microRNAs, apoptosis blockade, and autophagy. Because resistance mechanisms can be present before chemotherapy even starts, and because drugs such as DNMT and HDAC inhibitors have re-sensitized resistant cells in trials and models, a second opinion can help clarify whether biomarker testing, epigenetic agents, or a clinical trial fits your situation. Seek one when your tumor stops responding to platinum drugs. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Chemoresistance in Ovarian Cancer and Association with Circadian Rhythm.

Authors: Pektopal FS, Kum Özşengezer S, Altun ZS.

Publication details: Reproductive Sciences (2026), volume 33, pages 1079–1090. Section: Gynecologic Oncology: Review. DOI: 10.1007/s43032-026-02093-9. Received 19 November 2024; Accepted 21 March 2026; Published online 4 May 2026. © The Author(s) 2026.

Keywords: Ovarian cancer, circadian rhythm, chemoresistance, cisplatin

This patient-friendly article is based on peer-reviewed research.